Back HIV Prevention Microbicides

Microbicides

CROI 2017: Bacterial Vaginosis Does Not Affect Efficacy of Oral PrEP in Women

Research presented at the Conference on Retroviruses and Opportunistic Infections last month in Seattle found that the efficacy of oral pre-exposure prophylaxis (PrEP) for women was not affected by bacterial vaginosis (BV) -- the overgrowth in the vagina of untypical microbes. The effectiveness of PrEP in the Partners PrEP study was not significantly different in women with and without BV. This rules out BV as a possible cause for the lower effectiveness of oral PrEP in some studies of women compared to studies of men who have sex with men.

alt

Read more:

HIVR4P 2016: New Microbicide Enema Achieves High Levels of Drug in Rectal Tissues in Monkeys

Rectal microbicides that protect against HIV transmission via anal sex are a bigger technical challenge than vaginal ones. The rectal lining is more delicate than the vaginal lining, so safety has been an issue; research has shown that many of the gel formulations used in lubricants damage rectal cells and may actually enhance HIV transmission.

alt

Read more:

NIAID To Fund Follow-Up Study of Dapivirine Vaginal Ring for HIV Prevention

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, will support an open-label continuation study of the dapivirine vaginal ring that demonstrated modest protection against HIV infection, especially among older women, in 2 clinical trials in Africa, as reported at the recent Conference on Retroviruses and Opportunistic Infections in Boston.

alt

Read more:

Coverage of HIV Research for Prevention Conference (HIVR4P 2016)

HIVandHepatitis.com coverage of the 2016 HIV Research for Prevention Conference (HIVR4P 2016), October 17-21, in Chicago.

Conference highlights include current and experimental pre-exposure prophylaxis (PrEP), microbicide rings and other options, and investigational HIV vaccines.

Full listing of coverage by topic

HIVR4P 2016 website

10/22/16

alt

CROI 2016: Maraviroc May Work as PrEP in a Combination, but Probably Not Alone

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston outlined the first findings from the NEXT-PrEP study, otherwise known as HPTN 069. What NEXT-PrEP has discovered so far indicates that the drug maraviroc (Selzentry) could have a role in pre-exposure prophylaxis, or PrEP, when used alongside either tenofovir or emtricitabine (the component drugs in Truvada), but is not potent enough to act as PrEP by itself.

alt

Read more: